Concepedia

Lead-likeness Optimization

Lead-Likeness Optimization is a pharmaceutical design strategy that systematically refines the physicochemical and structural properties of bioactive compounds to meet criteria associated with favorable absorption, distribution, metabolism, and excretion (ADME) while maintaining sufficient potency and selectivity, thereby enhancing their suitability as development candidates in drug discovery.

23

Publications

7.2K

Citations

171

Authors

40

Institutions

Publications per year

2017–2026

11

Parents

Publications

23

Lead- and drug-like compounds: the rule-of-five revolution

Christopher A. Lipinski · Drug Discovery Today Technologies · 2004 · 6.1K citations

, , +14

Molecular Property Design: Does Everyone Get It?

Paul D. Leeson, Robert J. Young · ACS Medicinal Chemistry Letters · 2015 · 147 citations

, , +13

<i>De Novo</i> Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization

Domenico Alberga, Nicola Gambacorta, Daniela Trisciuzzi et al. · Journal of Chemical Information and Modeling · 2020 · 90 citations · Full text

, , +14

Ring‐Expansion Approach to Medium‐Sized Lactams and Analysis of Their Medicinal Lead‐Like Properties

Laetitia G. Baud, Morgan A. Manning, Helen L. Arkless et al. · Chemistry - A European Journal · 2016 · 80 citations

, , +17

Recent advances in the synthesis of xanthones and azaxanthones

Diana I. S. P. Resende, Fernando Durães, Miguel Maia et al. · Organic Chemistry Frontiers · 2020 · 79 citations

, , +14

1–5 of 23

Authors

171

  1. KD
    Kevin D. Freeman‐Cook

    Pfizer (United States), United States

    2 publications · 131 citations

    2

    h-index

  2. KL
    K. LeRoi Nelson

    Pfizer (United States), United States

    2 publications · 131 citations

    2

    h-index

  3. MJ
    Magdalena Jastrzębska‐Więsek

    Jagiellonian University, Poland

    1 publications · 47 citations

    1

    h-index

  4. JH
    Jadwiga Handzlik

    Jagiellonian University, Poland

    1 publications · 47 citations

    1

    h-index

  5. CH
    Chin-Ting Huang

    National Health Research Institutes, Taiwan

    1 publications · 41 citations

    1

    h-index

1–5 of 171

Institutions

40

  1. Pfizer (United States)

    New York, United States

    3 h-index

    52 publications

    9.4K citations

  2. Chinese Academy of Sciences

    Beijing, China

    2 h-index

    6 publications

    222 citations

  3. Loughborough University

    Loughborough, United Kingdom

    2 h-index

    5 publications

    135 citations

  4. Rede de Química e Tecnologia

    Porto, Portugal

    1 h-index

    5 publications

    395 citations

  5. AstraZeneca (Singapore)

    Singapore, Singapore

    1 h-index

    1 publications

    24 citations

  6. Center for Excellence in Brain Science and Intelligence Technology

    Shanghai, China

    1 h-index

    2 publications

    146 citations

  7. Medicina

    Krakow, Poland

    1 h-index

    2 publications

    94 citations

  8. Shanghai Institute of Organic Chemistry

    Shanghai, China

    1 h-index

    4 publications

    76 citations

1–8 of 40

Venues

  1. Journal of Medicinal Chemistry

    4 publications · 221 citations

    4

    h-index

  2. Journal of Chemical Information and Modeling

    JCIM · 2 publications · 109 citations

    2

    h-index

  3. ACS Medicinal Chemistry Letters

    2 publications · 166 citations

    2

    h-index

  4. Chemistry - A European Journal

    1 publications · 80 citations

    1

    h-index

  5. ChemMedChem

    1 publications · 24 citations

    1

    h-index

1–5